Molecular Data Inc. (MKD) Comparison with companies in other sectors?

Molecular Data Inc. has a share price of N/A. You can analyze Molecular Data Inc. (MKD) competitors across different market sectors through stock heatmaps.

What are MKD's NET and operating margins?

Molecular Data Inc. (MKD) operating margin is around -0.04, and net profit margin is approximately -0.04 as of the latest reports.

In what way does MKD's earnings per share (EPS) trend reflect its financial momentum?

Molecular Data Inc. (MKD) EPS is -3.85 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Molecular Data Inc. is -0.11, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Molecular Data Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Molecular Data Inc. like P/E which is -1.12, P/B which is -13.19, and PEG which is -0.00. Compare them with sector averages to evaluate if the stock is priced fairly.

Molecular Data Inc.

MKD•NASDAQ

Basic Materials

Chemicals

$0.41

$0.010(2.50%)

Fundamental Analysis of Molecular Data Inc. (MKD)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-3.85

P/E Ratio

-0.11

ROE

2.68%

Net Margin

-0.04%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$0.00

Shares OutstandingTotal number of shares issued

Book Value/ShareNet worth per share

$-0.22

Revenue/ShareAnnual revenue per share

$60.60

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-3.854

Net MarginNet income as percentage of revenue

-4.32%

Operating MarginOperating income as percentage of revenue

-4.36%

ROEReturn on shareholders' equity

268.42%

ROAReturn on total assets

-47.90%

ROCEReturn on capital employed

4258.92%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-1.87

Cash/ShareCash and equivalents per share

$2.77

FCF YieldFree cash flow as percentage of market cap

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for MKDFinancial Ratios Analysis details for MKD are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for MKDSector Benchmarking details for MKD are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Molecular Data Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Molecular Data Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Molecular Data Inc.'s unique business strengths and challenges.

Key Financial Metrics for Molecular Data Inc.

For Molecular Data Inc., essential financial indicators include EPS -3.85, PE -0.11, and ROE 2.68. These key ratios reveal insights into Molecular Data Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Molecular Data Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Molecular Data Inc.

Metrics like Net Margin -4.32% and ROA -47.90% shed light on how well Molecular Data Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Molecular Data Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Molecular Data Inc.

Using ratios such as P/B Ratio -13.19 and PEG Ratio -0.00, investors can assess whether Molecular Data Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Molecular Data Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Molecular Data Inc.

Financial health indicators, such as Debt/Equity Ratio -2.55 and Cash Flow $-1.87, provide a snapshot of Molecular Data Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Molecular Data Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Molecular Data Inc.

Investing in Molecular Data Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Molecular Data Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;